329 related articles for article (PubMed ID: 25592091)
1. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review.
Thakur D; Dickerson S; Kumar Bhutani M; Junor R
Clin Ther; 2015 Jan; 37(1):212-24. PubMed ID: 25592091
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.
Coluzzi F; Ruggeri M
Curr Med Res Opin; 2014 Jun; 30(6):1139-51. PubMed ID: 24528146
[TBL] [Abstract][Full Text] [Related]
4. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
[TBL] [Abstract][Full Text] [Related]
5. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
Kern KU; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
Lange B; von Zabern D; Elling C; Dubois C
Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
[TBL] [Abstract][Full Text] [Related]
8. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
Etropolski M; Kelly K; Okamoto A; Rauschkolb C
Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
[TBL] [Abstract][Full Text] [Related]
9. Effect of tapentadol extended release on productivity: results from an analysis combining evidence from multiple sources.
Cepeda MS; Sutton A; Weinstein R; Kim M
Clin J Pain; 2012 Jan; 28(1):8-13. PubMed ID: 21646907
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials.
Lange B; Sohns M; Tempero J; Elling C
Curr Med Res Opin; 2018 Dec; 34(12):2113-2123. PubMed ID: 30200781
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.
Serrie A; Lange B; Steup A
Curr Med Res Opin; 2017 Aug; 33(8):1423-1432. PubMed ID: 28537501
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
[TBL] [Abstract][Full Text] [Related]
14. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
[TBL] [Abstract][Full Text] [Related]
15. Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders.
Hwang CJ; Chung SS; Lee KY; Lee JH; Moon SH; Kim JH; Cho KJ; Ahn JS; Kim DS; Park YS; Park HJ
Clin Orthop Surg; 2018 Mar; 10(1):33-40. PubMed ID: 29564045
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
[TBL] [Abstract][Full Text] [Related]
17. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
[TBL] [Abstract][Full Text] [Related]
18. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study.
Guerriero F; Roberto A; Greco MT; Sgarlata C; Rollone M; Corli O
Drug Des Devel Ther; 2016; 10():1515-23. PubMed ID: 27143857
[TBL] [Abstract][Full Text] [Related]
20. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.
Vorsanger G; Xiang J; Biondi D; Upmalis D; Delfgaauw J; Allard R; Moskovitz B
Pain Res Manag; 2011; 16(4):245-51. PubMed ID: 22059194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
